Doxycycline Plus Bortezomib-Containing Regimens for the Treatment of Light-Chain Amyloidosis in the Frontline Setting: Experience from the Amyloidosis Program of Calgary.

MLA

Lewis, Ellen, et al. “Doxycycline Plus Bortezomib-Containing Regimens for the Treatment of Light-Chain Amyloidosis in the Frontline Setting: Experience from the Amyloidosis Program of Calgary.” Current Oncology (Toronto, Ont.), vol. 31, no. 9, Sept. 2024, pp. 5608–16. EBSCOhost, https://doi.org/10.3390/curroncol31090415.

APA

Lewis, E., Fine, N., McCulloch, S., Tay, J., Duggan, P., Neri, P., Bahlis, N., & Jimenez-Zepeda, V. H. (2024). Doxycycline Plus Bortezomib-Containing Regimens for the Treatment of Light-Chain Amyloidosis in the Frontline Setting: Experience from the Amyloidosis Program of Calgary. Current Oncology (Toronto, Ont.), 31(9), 5608–5616. https://doi.org/10.3390/curroncol31090415

Chicago

Lewis, Ellen, Nowell Fine, Sylvia McCulloch, Jason Tay, Peter Duggan, Paola Neri, Nizar Bahlis, and Victor H Jimenez-Zepeda. 2024. “Doxycycline Plus Bortezomib-Containing Regimens for the Treatment of Light-Chain Amyloidosis in the Frontline Setting: Experience from the Amyloidosis Program of Calgary.” Current Oncology (Toronto, Ont.) 31 (9): 5608–16. doi:10.3390/curroncol31090415.